Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2005

01-05-2005

Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group

Authors: Chihiro Shimazaki, Hiroshi Fujii, Takashi Yoshida, Takaaki Chou, Miki Nishimura, Hideki Asaoku, Shuichi Miyawaki, Akihiro Ishii, Tadao Ishida, Masafumi Taniwaki, Shinsuke Iida, Toshiyuki Takagi, Kiyoshi Takatsuki

Published in: International Journal of Hematology | Issue 4/2005

Login to get access
Metadata
Title
Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group
Authors
Chihiro Shimazaki
Hiroshi Fujii
Takashi Yoshida
Takaaki Chou
Miki Nishimura
Hideki Asaoku
Shuichi Miyawaki
Akihiro Ishii
Tadao Ishida
Masafumi Taniwaki
Shinsuke Iida
Toshiyuki Takagi
Kiyoshi Takatsuki
Publication date
01-05-2005
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2005
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04174

Other articles of this Issue 4/2005

International Journal of Hematology 4/2005 Go to the issue

OriginalPaper

Human Herpesvirus 6 Variant B Infection in Adult Patients after Unrelated Cord Blood Transplantation

OriginalPaper

The Maturation of Myeloma Cells Correlates with Sensitivity to Chemotherapeutic Agents

Case Report

Fatal Fulminant Hepatitis B after Withdrawal of Prophylactic Lamivudine in Hematopoietic Stem Cell Transplantation Patients

OriginalPaper

Of Mice, Flies, and Man: The Emerging Role of Polycomb-Group Genes in Human Malignant Lymphomas

OriginalPaper

Epigenetic Regulation of Hematopoietic Stem Cell Self-Renewal by Polycomb Group Genes

OriginalPaper

CD56/NCAM-Positive Langerhans Cell Sarcoma: A Clinicopathologic Study of 4 Cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits